A Precision Health Approach to Post-Treatment Comorbid Diabetes in Cancer With Marilyn Hammer, PhD, DC, RN, FAAN
Expert Perspectives · Keira Smith · 2024-06-06
At this year’s Oncology Nursing Society (ONS) Congress, Marilyn Hammer, PhD, DC, RN, FAAN, Director of the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at the Dana-Farber Cancer Institute, presented a session entitled Precision Health Oncology: Focus on Post-Treatment Comorbid Diabetes.
In this interview, she delves further into precision health approaches to post-treatment comorbid diabetes in cancer and discusses:
- Known associations between cancer treatment and diabetes
- Negative impacts on quality of life and treatment outcomes that diabetes presents for patients with cancer
- The COACH study, for which she is co–primary investigator, and the significance of sugar intake, glycemic index, and fatigue that it found
- Future research opportunities on this topic
- Goals for translating this research into clinical practice
- And more!
About Dr. Hammer
Marilyn Hammer, PhD, DC, RN, FAAN, is the Director of the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at the Dana-Farber Cancer Institute. Dr. Hammer’s research is focused on precision health symptom science, with ongoing research currently studying associations between glycemic status and immune function.